By 2030, orphan drugs will make up fifth of the forecast $1.6 trillion in worldwide prescription drug sales – a share that has doubled over the last decade. The lines between niche drugs for rare diseases and mainstream prescription drugs are blurring rapidly.
In this infographic we summarize some of the key data points that highlight this shift, including:
- The slowdown in growth in the orphan drugs market
- Forecasts for the top-selling orphan drugs in 2030
- The most promising therapies in the orphan drug pipeline.
